The REDEFINE 1 and 2 trials evaluated the effects of cagrilintide 2.4 mg and semaglutide 2.4 mg on weight loss in patients with overweight or obesity, with and without type 2 diabetes
Patient Platforms Onboarding & eligibility flows Progress tracking & reminders Education, coaching & community Telehealth & Provider Tools Scheduling & care coordination Video consults & secure messaging Treatment protocols Medication Management E-prescribing to retail & compounding Refill & fulfillment tracking Insurance & Billing Eligibility checks, prior auths & appeals Subscriptions, cash-pay, and transparent billing Foundation for Growth HIPAA-ready infrastructure Integrations with your existing systems (like EHR, labs and pharmacy) Analytics & business insights Engagement & Retention Personalized nudges & reminders Gamification & milestone tracking Patient satisfaction surveys Experts in Digital Health Were Light-ita digital health product studio
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Senators repeatedly press CEO to lower list prices in the USpublished at 16:41 BST 24 September 2024 Senator Maggie Hassan pointedly asks Novo Nordisk's CEO: "Would you please commit to lowering the list price of these drugs?" This question has been repeatedly aimed at Lars Jrgensen throughout the hearing, now passing the 90-minute mark
For travelers, understanding what happens when semaglutide gets warm becomes a practical concern
Kieburtz K, Katz R, McGarry A, Olanow CW